Clinical PerformanceNuvation Bio's Ibtrozi showed a median progression-free survival of approximately 4 years, outperforming peers with up to 3 years.
Guideline InclusionThe National Comprehensive Cancer Network added Nuvation Bio's Ibtrozi as the preferred option to clinical practice guidelines in oncology for advanced ROS1+ NSCLC.
ValuationNUVB is undervalued compared to its peers, trading at a significantly lower enterprise value, suggesting potential for increased investor confidence.